MetaStat, Inc. (OTCQB:MTST), a pre-commercial biotechnology
company focused on the development and commercialization of companion
diagnostics and anti-metastatic therapeutics in the novel cancer
treatments in drugs, today announced the promotion of Jerome B. Zeldis,
M.D., Ph.D. from Vice Chairman to Chairman and the appointment of
Douglas A. Hamilton, MetaStat's President and Chief Executive Officer,
to its board of directors in connection with a restructuring of
MetaStat's board.
Dr. Zeldis stated, "MetaStat has an exciting technology platform based
on the novel mechanisms that drive cancer metastasis and overcome tumor
resistance to certain therapeutics, creating the potential to discover
novel cancer drugs. I look forward to working with Doug and the MetaStat
team in solidifying our mission to discover and develop truly novel
approaches for treating a variety of cancers."
Mr. Hamilton said, "I am delighted Jerry is leading MetaStat's Board of
Directors and honored to serve on the board with him. We have a shared
vision for the future of the Company, seeing multiple opportunities to
make significant advances in treating cancer." Mr. Hamilton continued,
"Our driver-based diagnostic biomarkers are also therapeutic targets for
the development of anti-metastatic drugs and combination therapies to
overcome drug resistance. We plan to leverage our driver-based
biomarkers and expand strategic partnerships to unlock opportunities in
oncology."
Please see the company's current report on Form 8-K filed with the
Securities and Exchange Commission on May 8, 2017 for full details on
the board restructuring, including the resignations of Messrs. Berman,
Goodeve and Bronsther.
Dr. Zeldis is the Chief Medical Officer of Sorrento Therapeutics, Inc.,
and previously served as Chief Medical Officer of Celgene Corporation
and Chief Executive Officer of Celgene Global Health until June 2016.
Prior to joining Celgene in 1997, Dr. Zeldis held positions at Sandoz
Research Institute and Janssen Research Institute in both clinical
research and medical affairs. He currently serves as Chairman of the
board of Alliqua and Trek Therapeutics, in addition to board positions
at PTC Therapeutics and Soligenix. He was Assistant Professor of
Medicine at Harvard Medical School, Associate Professor of Medicine at
University of California, Davis, Clinical Associate Professor of
Medicine at Cornell Medical School, and Professor of Clinical Medicine
at the Robert Wood Johnson Medical School. Dr. Zeldis received BA and MS
degrees from Brown University, and M Phil, MD, and PhD degrees from Yale
University. Dr. Zeldis has published 122 peer-reviewed articles and is a
named inventor on 43 U.S. patents.
Mr. Hamilton has been President and CEO of MetaStat since June 2015.
Previously, Mr. Hamilton served as CFO for SEA Medical Systems and since
2007, Partner at New Biology Ventures, a life-sciences incubator
accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served
as CFO and COO for Javelin Pharmaceuticals, purchased by Hospira, where
he led the company to commercialization and through its successful
national markets up-listing. Prior to Javelin, Mr. Hamilton was the CFO
and Director of Business Development for PolaRx Biopharmaceuticals (now
Teva Pharmaceuticals). Mr. Hamilton held positions at Amgen and Pfizer
in clinical research and product development, sales and marketing at
Pharmacia Biotechnology (now GE Healthcare Life Sciences), and research
at Connaught Laboratories (now Sanofi-Pasteur). Mr. Hamilton earned his
honors Bachelor of Science degree from the Department of Medical
Genetics at the University of Toronto and his MBA from the Ivey Business
School at Western University.
About MetaStat, Inc.
MetaStat is a pre-commercial biotechnology company focused on the
discovery, development and commercialization of diagnostics tests that
are prognostic for risk of cancer metastasis, companion diagnostics to
predict drug response and therapeutics to prevent aggressive cancer from
spreading. MetaStat's driver-based diagnostic and therapeutic discovery
platform technology is based on the pivotal role of the Mena protein and
its isoforms, a common pathway for the development of metastatic disease
and drug resistance in all epithelial-based solid tumors. MetaStat is
based in Boston, MA.
Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the company's Form 10-K and its other filings filed
with the Securities and Exchange Commission. You should consider these
factors in evaluating the forward-looking statements included herein,
and not place undue reliance on such statements. The forward-looking
statements in this release are made as of the date hereof and the
company undertakes no obligation to update such statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170508005771/en/
